PeptiDream: Powering Next-Gen Peptide Therapeutics with a Proprietary Discovery Platform Behind $5.7B in Recent Strategic Deals

With the advancement of omics technologies, information technology, and gene technology, as well as in-depth research into disease biology, techniques such as rational peptide drug design, virtual screening, high-throughput synthesis, structural modification, and formulation processes have been continuously refined, giving rise to representative companies of the “new peptide economy.”PeptiDream is the most influential technology-driven biopharmaceutical company in the global peptide industry.

PeptiDream is a Japanese biopharmaceutical CRO company that owns a proprietary Peptide Discovery Platform System (PDPS). This system enables the high-efficiency production of highly diverse non-standard peptide libraries for the identification of high-potency and selective hit peptides, which are then developed into peptide-based, small-molecule, or peptide-conjugate therapies. Since its initial public offering in 2013, PeptiDream has evolved from a laboratory startup into the most profitable company in Japan’s pharmaceutical industry, with its technology attracting numerous global pharmaceutical giants, including Novartis, Genentech, Merck, AstraZeneca, and Takeda Pharmaceutical Company.

PeptiDream’s business model is built on its core technology platform, PDPS, which has enabled three revenue streams: 1) R&D collaborations; 2) technology licensing; and 3) internal R&D.

1) R&D Collaboration: In accordance with the pharmaceutical company’s objectives, a small upfront fee is charged initially, followed by the application of the PDPS technology platform. If the PDPS technology successfully identifies or screens suitable target peptide compounds, PeptiDream receives substantial milestone payments.

2) Technology Transfer: PeptiDream licenses its PDPS technology to pharmaceutical companies for in-house laboratory use. The pharmaceutical companies pay an upfront one-time licensing fee, followed by annual technology transfer and maintenance fees payable approximately one year later.

(3) In-house R&D: PeptiDream leverages its PDPS technology to conduct internal research and development of novel peptide compounds, which are then licensed to interested pharmaceutical companies. Under this model, pharmaceutical partners are required to make preclinical, clinical, and commercial milestone payments for products under development. This business model offers greater scalability and more substantial payment potential compared to the two aforementioned models.

On July 27 and July 29 of last year, within a span of three days,PeptiDream has successively announced partnerships withTakeda Pharmaceutical and Alnylam Reach Collaboration, Signing $3.5 Billion and $2.2 Billion Agreements Respectively, Drawing Widespread Industry Attention

Why Did Takeda Pharmaceutical and Alnylam Choose to Bet on PeptiDream’s Core Technology Platform?

In 1997, Professor Hiroaki Suga, a co-founder of PeptiDream, earned his Ph.D. in Chemistry from the Massachusetts Institute of Technology and taught at the University at Buffalo.Hiroaki Suga's research has discovered a ribozyme capable of arbitrarily combining over 400 different amino acids with tRNA., whereas existing peptide synthesis systems can only utilize the 20 natural amino acid molecules,Hiroaki Suga named it Flexizyme, which has become the foundational core technology of PeptiDream.

PeptiDream’s PDPS core technology comprises three components: Flexizyme and peptide translation technology; cyclization and modification technology; and PD display technology.

1) Flexizyme Technology and PDTS (Peptide Discovery Translation System)

Traditional ribosome-synthesized polypeptides are mainly formed by sequentially linking amino acids to the peptide chain through the transport function of tRNA and the complementary base pairing between tRNA and the ribosome. This process typically occurs within the cells of living organisms and involves two key reactions: 1. Aminoacyl-tRNA synthetases (ARSs) catalyze the attachment of amino acids to their respective tRNAs; 2. tRNA pairs with mRNA via recognition at the ribosome. The first reaction can be applied to in vitro polypeptide synthesis: recombinant ARSs can be used to conjugate special amino acids (AAs) with tRNA, but the substrate hybridization efficiency is low.

Flexizyme can efficiently catalyze the conjugation of natural and non-canonical amino acids to tRNA, forming aminoacyl-tRNA complexes in preparation for subsequent translation.

PDTS is the synthesis system for the second key reaction mentioned above: a cell-free transcription/translation system for ribosome-synthesized peptides. When PDTS is used alone, it can only synthesize peptides composed of the 20 natural amino acids; however, when combined with Flexizyme technology, it enables the synthesis of diverse peptides using more than 400 types of non-natural amino acids.

2) Peptide Cyclization and Modification Technologies: Another Key Enabling Technology for PDPSCyclization of Various Linear Peptides and Their Conversion into Specialized Cyclic Peptides. Peptide cyclization technology modifies the functional group at one end of the peptide chain, enabling it to undergo a chemical reaction that links the N- and C-termini, thereby forming a cyclic peptide.

Compared with common linear peptides, specialized cyclic peptides offer many advantages, such as greater structural rigidity, higher affinity and selectivity for target proteins, and enhanced stability in vivo. PDPS also incorporates various other specialized peptide modification technologies, which can significantly reduce the time required for hit peptide screening.

3) PD Display (PeptiDream Display) The aforementioned two technologies enable the rapid preparation of diverse peptide libraries. The next step is to identify hit peptides with potential therapeutic effects from libraries containing thousands of peptides.Compared with other display technologies, PD display can identify and screen hit peptides in a short time, with extremely high reproducibility and repeatability. The company continuously optimizes PD display to match the peptide flow technology under research.

Image source: PeptiDream official website

PeptiDream currently has 124 drug development pipelines, most of which are in the drug discovery and preclinical stages, with four projects having entered Phase I clinical trials.

PeptiDream’s success was not achieved overnight; its PDPS technology platform required a lengthy adoption period and has undergone more than 20 years of technical validation in commercial applications. Typically, developing a peptide platform demands an experienced team to spend years incubating the technology before proceeding with platform-level validation. PeptiDream’s advantage lies in its core foundational technologies and a team of over 20 full-time scientists deeply engaged in the peptide field. By investing sufficient time and patience to accumulate technical expertise, the company has completed the qualitative transformation from research to application, from accumulation to creation, and from creation to breakthrough.

Therapies such as mRNA, siRNA, antisense oligonucleotides, and RNA activation (RNAa) have infused the nucleic acid drug sector with diverse new possibilities for treating human diseases. Amid the ongoing emergence of novel technologies, peptide delivery systems have become pivotal to the therapeutic efficacy of nucleic acid drugs.

Alnylam leverages PeptiDream’s peptide discovery platform to select a series of receptors for its small nucleic acid drug pipeline, with PeptiDream responsible for the selection, optimization, and synthesis of peptides for each receptor.Subsequently, Alnylam will generate peptide-siRNA conjugates and conduct in vitro and in vivo studies to select the most suitable peptides. By targeting pathogenic mRNA transcripts across multiple tissue types, the company aims to explore therapeutic opportunities for a variety of diseases.

Dr. Kevin Fitzgerald, Chief Scientific Officer at Alnylam, stated: “We are delighted to collaborate with PeptiDream and hope that the PDPS platform will enable the identification of robust ligand–receptor pairs for extrahepatic tissues, address the challenges of delivering RNAi therapeutics beyond the liver, and advance siRNA drug delivery to human central nervous system (CNS), ocular, and pulmonary tissues.”

As a class of small nucleic acid drugs within the RNA interference (RNAi) category, siRNA has broad clinical indications and can be used for tumors, rare diseases, viral infections, cardiovascular diseases, inflammatory conditions, and more. However, siRNA drugs preferentially target the kidneys and liver, are susceptible to degradation by nucleases, and cannot cross the blood-brain barrier, thereby limiting their tissue targeting capabilities. Peptides have emerged as widely recognized “ideal” carriers for nucleic acid delivery due to their excellent biocompatibility, biodegradability, and flexibility in chemical modification, which allow them to meet diverse clinical needs. Compared with peptides alone, peptide-drug conjugates (PDCs) offer additional functionalities, such as improved drug solubility, enhanced target selectivity, and the ability to circumvent multidrug resistance.

In July 2021, Takeda Pharmaceutical Company and PeptiDream expanded their research collaboration and licensing agreement to develop peptide-drug conjugates (PDCs) for chronic neurodegenerative diseases. This collaboration focuses on expanding the application of TfR1-binding peptide ligands for central nervous system (CNS) targets associated with neurodegenerative diseases. When conjugated with various therapeutic payloads, TfR1-binding peptide carriers enable the payloads to cross the blood-brain barrier, thereby significantly enhancing therapeutic efficacy.

Under the terms of the agreement, PeptiDream will receive approximately $3.5 billion in collaboration fees. In addition, it will also receive royalty payments based on Takeda’s net sales of the product.

It is worth noting that the peptide-drug conjugate (PDC) for neuromuscular diseases was initially developed by PeptiDream.PDCs covalently link specific peptide sequences to cytotoxins via a cleavable linker, targeting diseased tissues to increase local cytotoxin concentration, mitigate toxicity in non-diseased tissues, reduce adverse reactions, and achieve the goal of enhanced efficacy with reduced toxicity.

“Since we began our research collaboration with PeptiDream, we have made significant progress. PeptiDream Inc.’s TfR1-binding technology offers an effective therapeutic approach for neurodegenerative diseases,” said the Director of the Neuroscience Therapeutic Area at Takeda.

PDCs integrate the advantages of peptides, featuring low molecular weight and biodegradability without eliciting immunogenic responses. By modifying the amino acid sequence of the peptide chain, the hydrophobicity and ionization properties of PDC conjugates can be altered to address issues such as poor water solubility and inadequate metabolic clearance, while enhancing cellular and tissue permeability. This approach overcomes the high attrition rate in clinical development of small-molecule drugs caused by suboptimal physicochemical properties.

Certain specific peptide carriers can also overcome tumor drug resistance and enable drug delivery across the blood-brain barrier. Furthermore, compared with antibody-drug conjugate (ADC) technology, peptide-drug conjugates (PDCs) offer several industrial advantages, such as superior homogeneity and lower production costs and shorter manufacturing cycles.

The collaboration between Alnylam and Takeda demonstrates recognition of the PeptiDream peptide discovery platform and its capability to identify and optimize compounds for clinical development. To date, PeptiDream has established partnerships with many leading global pharmaceutical companies, including Amgen, AstraZeneca, Genentech, Eli Lilly, BMS, GlaxoSmithKline, Novartis, Merck, and Mitsubishi Tanabe Pharma.

Meanwhile, VBInsight has found that PeptiDream’s partner companies demonstrate a 70% rate of continued adoption of PDPS technology for their future product pipelines, positioning PeptiDream as the top choice among global large pharmaceutical companies for peptide discovery platforms.